A61P 39/02
Antidotes
A61P39/02 (Antidotes) appears on 2,227 US grants and 3,062 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,227
- Published applications
- 3,062
- Assignees
- 1,389
- Inventors
- 6,124
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 4 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 16 | 0 |
| 1983 | 8 | 0 |
| 1984 | 2 | 0 |
| 1985 | 4 | 0 |
| 1986 | 8 | 0 |
| 1987 | 7 | 0 |
| 1988 | 14 | 0 |
| 1989 | 14 | 0 |
| 1990 | 9 | 0 |
| 1991 | 24 | 0 |
| 1992 | 9 | 0 |
| 1993 | 9 | 0 |
| 1994 | 15 | 0 |
| 1995 | 10 | 0 |
| 1996 | 19 | 0 |
| 1997 | 30 | 0 |
| 1998 | 35 | 0 |
| 1999 | 54 | 0 |
| 2000 | 36 | 0 |
| 2001 | 36 | 9 |
| 2002 | 47 | 57 |
| 2003 | 45 | 123 |
| 2004 | 44 | 122 |
| 2005 | 36 | 134 |
| 2006 | 58 | 132 |
| 2007 | 47 | 143 |
| 2008 | 70 | 149 |
| 2009 | 65 | 163 |
| 2010 | 103 | 151 |
| 2011 | 67 | 159 |
| 2012 | 115 | 150 |
| 2013 | 129 | 166 |
| 2014 | 121 | 163 |
| 2015 | 123 | 159 |
| 2016 | 111 | 181 |
| 2017 | 132 | 169 |
| 2018 | 115 | 145 |
| 2019 | 96 | 126 |
| 2020 | 85 | 107 |
| 2021 | 64 | 89 |
| 2022 | 58 | 64 |
| 2023 | 34 | 58 |
| 2024 | 40 | 71 |
| 2025 | 30 | 42 |
| 2026 | 19 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Honeybee antidote composition6 Oct 2026US 12,751,933 B2Andong National University Industry-Academic Cooperation Foundation
- Use of SPLA2 inhibitors to treat envenomation by snakes and wasps25 Aug 2026US 12,714,693 B2Ophirex, Inc.
- Compositions and methods for treating heart failure18 Aug 2026US 12,708,658 B2Zensun (Shanghai) Science & Technology, Co., Ltd.
- Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof11 Aug 2026US 12,703,762 B2Novartis AG
- Thiophenoxime and furanoxime scaffolds14 Jul 2026US 12,679,831 B2Centre National De La Recherche Scientifique
- Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers8 Oct 2026US 2026/0306589 A1Goa Therapeutics Corporation
- Use of pentoxifylline in preparation of medicament for repairing endothelial glycocalyx damage10 Sep 2026US 2026/0263472 A1Air Force Medical University
- Potassium channel blockers or derivatives thereof for preventing, alleviating, and/or treating tissue dysfunction caused by toxic insults27 Aug 2026US 2026/0248773 A1University of Rochester
- Method for improving neurological function in mpsi and mpsii and other neurological disorders20 Aug 2026US 2026/0241038 A1Regents of the University of Minnesota
- Platinum complexes, related compositions, and uses thereof in cyanide counter-measures30 Jul 2026US 2026/0216120 A1Beth Israel Deaconess Medical Center, Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Treatment of damaged bone marrow and dosage units therefor585US 4,938,949 AUniversity of New York · 1990
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Human antibodies that bind human TNFα308US 6,258,562 B1BASF SE · 2001
- Human antibodies that bind human TNFa212US 6,509,015 B1BASF SE · 2003